86 related articles for article (PubMed ID: 31513636)
1. PRC2 activates interferon-stimulated genes indirectly by repressing miRNAs in glioblastoma.
Shivram H; Le SV; Iyer VR
PLoS One; 2019; 14(9):e0222435. PubMed ID: 31513636
[TBL] [Abstract][Full Text] [Related]
2. Polycomb Repressive Complex 2 in Oncology.
Guo Y; Yu Y; Wang GG
Cancer Treat Res; 2023; 190():273-320. PubMed ID: 38113005
[TBL] [Abstract][Full Text] [Related]
3. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition.
Romero P; Richart L; Aflaki S; Petitalot A; Burton M; Michaud A; Masliah-Planchon J; Kuhnowski F; Le Cam S; Baliñas-Gavira C; Méaudre C; Luscan A; Hamza A; Legoix P; Vincent-Salomon A; Wassef M; Holoch D; Margueron R
Nat Commun; 2024 Apr; 15(1):3452. PubMed ID: 38658543
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.
Wan L; Xu K; Wei Y; Zhang J; Han T; Fry C; Zhang Z; Wang YV; Huang L; Yuan M; Xia W; Chang WC; Huang WC; Liu CL; Chang YC; Liu J; Wu Y; Jin VX; Dai X; Guo J; Liu J; Jiang S; Li J; Asara JM; Brown M; Hung MC; Wei W
Mol Cell; 2018 Jan; 69(2):279-291.e5. PubMed ID: 29351847
[TBL] [Abstract][Full Text] [Related]
5. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma.
Zhang L; Li HT; Shereda R; Lu Q; Weisenberger DJ; O'Connell C; Machida K; An W; Lenz HJ; El-Khoueiry A; Jones PA; Liu M; Liang G
Cancer Lett; 2022 Nov; 548():215899. PubMed ID: 36087682
[TBL] [Abstract][Full Text] [Related]
6. Polycomb repressive complex 2 and its core component EZH2: potential targeted therapeutic strategies for head and neck squamous cell carcinoma.
Cheng Y; Song Z; Fang X; Tang Z
Clin Epigenetics; 2024 Apr; 16(1):54. PubMed ID: 38600608
[TBL] [Abstract][Full Text] [Related]
7. EZH2 can be used as a therapeutic agent for inhibiting endothelial dysfunction.
Sun L; Li X; Luo H; Guo H; Zhang J; Chen Z; Lin F; Zhao G
Biochem Pharmacol; 2023 Jul; 213():115594. PubMed ID: 37207700
[TBL] [Abstract][Full Text] [Related]
8. Advances in bi-directional relationships for EZH2 and oxidative stress.
Qin H; Liu C; Li C; Feng C; Bo Huang
Exp Cell Res; 2024 Jan; 434(1):113876. PubMed ID: 38070859
[TBL] [Abstract][Full Text] [Related]
9. Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin.
Lee CH; Yu JR; Kumar S; Jin Y; LeRoy G; Bhanu N; Kaneko S; Garcia BA; Hamilton AD; Reinberg D
Mol Cell; 2018 May; 70(3):422-434.e6. PubMed ID: 29681499
[TBL] [Abstract][Full Text] [Related]
10. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing.
Fong KW; Zhao JC; Lu X; Kim J; Piunti A; Shilatifard A; Yu J
Mol Cell; 2022 Dec; 82(24):4611-4626.e7. PubMed ID: 36476474
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.
Lewis PW; Müller MM; Koletsky MS; Cordero F; Lin S; Banaszynski LA; Garcia BA; Muir TW; Becher OJ; Allis CD
Science; 2013 May; 340(6134):857-61. PubMed ID: 23539183
[TBL] [Abstract][Full Text] [Related]
12. Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.
Chen F; Byrd AL; Liu J; Flight RM; DuCote TJ; Naughton KJ; Song X; Edgin AR; Lukyanchuk A; Dixon DT; Gosser CM; Esoe DP; Jayswal RD; Orkin SH; Moseley HNB; Wang C; Brainson CF
Nat Commun; 2023 Jan; 14(1):336. PubMed ID: 36670102
[TBL] [Abstract][Full Text] [Related]
13. Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma.
Pang F; Zhang L; Li M; Yi X; Wang Y; Yang P; Wen B; Jiang J; Teng Y; Yang X; Chen L; Xu J; Wang L
Cancer Gene Ther; 2023 Dec; 30(12):1636-1648. PubMed ID: 37726387
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for inactivation of PRC2 by G-quadruplex RNA.
Song J; Gooding AR; Hemphill WO; Love BD; Robertson A; Yao L; Zon LI; North TE; Kasinath V; Cech TR
Science; 2023 Sep; 381(6664):1331-1337. PubMed ID: 37733873
[TBL] [Abstract][Full Text] [Related]
15. PRC2 Is Required to Maintain Expression of the Maternal Gtl2-Rian-Mirg Locus by Preventing De Novo DNA Methylation in Mouse Embryonic Stem Cells.
Das PP; Hendrix DA; Apostolou E; Buchner AH; Canver MC; Beyaz S; Ljuboja D; Kuintzle R; Kim W; Karnik R; Shao Z; Xie H; Xu J; De Los Angeles A; Zhang Y; Choe J; Jun DL; Shen X; Gregory RI; Daley GQ; Meissner A; Kellis M; Hochedlinger K; Kim J; Orkin SH
Cell Rep; 2015 Sep; 12(9):1456-70. PubMed ID: 26299972
[TBL] [Abstract][Full Text] [Related]
16. PRC2 is high maintenance.
Yu JR; Lee CH; Oksuz O; Stafford JM; Reinberg D
Genes Dev; 2019 Aug; 33(15-16):903-935. PubMed ID: 31123062
[TBL] [Abstract][Full Text] [Related]
17. Polycomb repressive complex 2 regulates MiR-200b in retinal endothelial cells: potential relevance in diabetic retinopathy.
Ruiz MA; Feng B; Chakrabarti S
PLoS One; 2015; 10(4):e0123987. PubMed ID: 25884496
[TBL] [Abstract][Full Text] [Related]
18. Single-cell sequencing reveals activation of core transcription factors in PRC2-deficient malignant peripheral nerve sheath tumor.
Zhang X; Lou HE; Gopalan V; Liu Z; Jafarah HM; Lei H; Jones P; Sayers CM; Yohe ME; Chittiboina P; Widemann BC; Thiele CJ; Kelly MC; Hannenhalli S; Shern JF
Cell Rep; 2022 Sep; 40(12):111363. PubMed ID: 36130486
[TBL] [Abstract][Full Text] [Related]
19. SUZ12 inhibition attenuates cell proliferation of glioblastoma via post-translational regulation of CDKN1B.
Kim S; Jo S; Paek SH; Kang SS; Chung H
Genes Genomics; 2023 Dec; 45(12):1623-1632. PubMed ID: 37856053
[TBL] [Abstract][Full Text] [Related]
20. Coordinated Actions of MicroRNAs with other Epigenetic Factors Regulate Skeletal Muscle Development and Adaptation.
Bianchi M; Renzini A; Adamo S; Moresi V
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28420141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
